



Subject: Topographic Genotyping (PathFinderTG, *PancraGEN*)*

Effective Date: December 13, 2011

Department(s): Utilization Management

Policy: Topographic genotyping, an integrated microsatellite marker-based mutational analysis on pathology specimens, is not reimbursable under Plans administered by QualCare, Inc.

Objective: To provide proper and consistent reimbursement and to exclude coverage of an unproven procedure.

Procedure: Requests for Pathfinder TG and PancraGEN analysis (topographic genotyping) will be denied. There is insufficient documentation in the peer reviewed literature of efficacy in aiding diagnosis, prognosis or treatment guidance. It is therefore deemed experimental investigational, or unproven.

There is no specific CPT code for this testing; it may be billed using the unlisted code 84999 or 81479.

References

Hayes Genetic test evaluation Report- PancraGEN (Interpace Diagnostics). HayesInc. Lansdale, PA. Published 11/22/16; annual review 9/17/17. Accessed at www.hayesinc.com

Xu MM, Yin S, Siddiqui AA, Salem RR, et al. Comparison of the diagnostic accuracy of three current guidelines for the evaluation of asymptomatic pancreatic cystic neoplasms. *Medicine (Baltimore)*. 2017;96(35):e7900(Sep)

Al-Haddad MA, Kowalski T, Siddiqui A, Mertz HR, Mallat D, Haddad N, Malhotra N, Sadowski B, Lybik MJ, Patel SN, Okoh E, Rosenkranz L, Karasik M, Golioto M, Linder J, Catalano MF. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. *Endoscopy*. 2015;47(2):136-42.(Feb)

Malhotra N, Jackson SA, Freed LL, Styn MA, Sidawy MK, Haddad NG, et al. The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center. *BMC Gastroenterol*. 2014;14:135(Aug)

Hayes Inc. Gene Test Evaluation Overview Report-Pathfinder TG® Test for Pancreatic Cancer- updated review 11/08/2013. Accessed at www.hayesinc.com

Park WG. Screening for pancreatic cancer: what can cyst fluid analysis tell us? *F100 Medicine Reports*. 2011;3:3(doi:10.33410/M3-3)(Feb)

Trikalinos TA, Terasawa T, Raman G, Ip S, Lau J. A systematic review of loss- of – heterozygosity based topographic genotyping with PathfinderTG®- Technology Assessment Report by the Tufts Evidence-based Practice Center for the Agency for Healthcare Research and Quality, March 1, 2010

Weinberg BM, Spiegel BM, Tomlinson JS, Farrell JJ. Asymptomatic pancreatic cyst neoplasms: maximizing survival and quality of life using markov-based clinical nomograms. *Gastroenterology* 2010;138(2):531-40(Feb)

Shen J, Brugge WR, Diminaio CJ, Pitman MB. Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. *Cancer Cytopathol*. 2009;117(3):217-27(June)

Khalid A, Zahid M, Finkelstein SD, LeBlanc JK, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. *Gastrointestinal Endoscopy*. 2009;69(6):1095-102(May)

Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of IPMN and mucinous cystic neoplasms of the pancreas. *Pancreatol* 2006;6:17–32.

Khalid A, McGrath KM, Zahid M, Wilson M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. *Clinical Gastroenterology and Hepatology*. 2005; 3(10):967-973(Oct)

Hunt JL, Finkelstein SD. Microdissection techniques for molecular testing in surgical pathology. *Arch Pathol Lab Med*. 2004; 128(12):1372-8(Dec)

Drafted By/Date: MMcNeil, MD 11/30/11

Approved By/Date: QM Committee 12/13/11

Reviewed w/o Revision By/Date: MMcNeil, MD 11/19/14

CONFIDENTIAL-NOT FOR DISTRIBUTION OUTSIDE OF QUALCARE

Approved By/Date: QM Committee 12/9/14
Revised By/Date: MMcNeil, MD 02/06/17
Approved By/Date: QM Committee 2/21/17
Revised By/Date: MMcNeil, MD 09/28/18
Approved By/Date: QM Committee 10/16/18

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.